Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

57.64 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15
Open 57.64
Bid (Size) 57.45 (200)
Ask (Size) 91.64 (100)
Prev. Close 57.64
Today's Range 57.64 - 57.64
52wk Range 5.666 - 57.70
Shares Outstanding 34,358,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Rapt Therapeutics Stock Soared Today ↗
A global healthcare giant wants to acquire the biotech's promising development program. 
Via The Motley Fool

Performance

YTD
+81.0%
+81.0%
1 Month
+62.8%
+62.8%
3 Month
+92.1%
+92.1%
6 Month
+355.7%
+355.7%
1 Year
+490.6%
+490.6%

More News

Read More
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
From Brodsky & Smith LLC
Via GlobeNewswire
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
Via MarketMinute
Topics Intellectual Property
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Why Did RAPT Stock Surge 63% In Pre-Market Today? ↗
Via Stocktwits
News headline image
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
Via The Motley Fool
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
From RAPT Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is RAPT Therapeutics, Inc. - Common Stock publicly traded?
Yes, RAPT Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does RAPT Therapeutics, Inc. - Common Stock trade on?
RAPT Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for RAPT Therapeutics, Inc. - Common Stock?
The ticker symbol for RAPT Therapeutics, Inc. - Common Stock is RAPT on the Nasdaq Stock Market
What is the current price of RAPT Therapeutics, Inc. - Common Stock?
The current price of RAPT Therapeutics, Inc. - Common Stock is 57.64
When was RAPT Therapeutics, Inc. - Common Stock last traded?
The last trade of RAPT Therapeutics, Inc. - Common Stock was at 01/22/26 04:00 PM ET
What is the market capitalization of RAPT Therapeutics, Inc. - Common Stock?
The market capitalization of RAPT Therapeutics, Inc. - Common Stock is 1.98B
How many shares of RAPT Therapeutics, Inc. - Common Stock are outstanding?
RAPT Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.